Sylvirene Milia Remover

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of milia, which are small skin bumps. It aids in the exfoliation of dead skin cells and helps to smooth skin texture.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Healthcare professionals are advised to cleanse and dry the affected skin area thoroughly prior to application. A thin layer of the product should be applied directly onto the milia (skin bumps) once or twice daily, depending on the severity of the condition and patient response. The product should be gently massaged into the skin until fully absorbed.

For optimal results, consistent use of the product for a duration of 4 weeks is recommended.

Contraindications

Use is contraindicated in the following situations:

Discontinue use if severe irritation develops. Avoid contact with eyes, lips, and mucous membranes; in the event of contact, rinse thoroughly with water. Application is contraindicated on broken, irritated, or sunburned skin.

Warnings and Precautions

For external use only. It is imperative that healthcare professionals advise patients to avoid contact with the eyes, lips, and mucous membranes. In the event of accidental contact, patients should be instructed to rinse the affected area thoroughly with water. Application to broken, irritated, or sunburned skin is contraindicated, as this may lead to excessive drying or peeling.

Patients should be closely monitored for any signs of severe irritation. If such irritation develops, it is essential to discontinue use immediately and consult a healthcare provider. Additionally, if the condition being treated worsens or fails to improve within four weeks, or if severe redness, burning, or swelling occurs, patients should be advised to seek medical attention promptly.

These precautions are critical to ensure the safe and effective use of the product.

Side Effects

Patients using this product should be aware that it is intended for external use only. In clinical practice, if the condition being treated worsens or does not show improvement within four weeks, patients are advised to discontinue use and consult a healthcare professional.

Additionally, patients should seek medical advice if they experience severe redness, burning, or swelling during treatment. These reactions may indicate a more serious issue that requires immediate attention. It is important for patients to monitor their symptoms closely and communicate any significant changes to their healthcare provider.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Sylvirene Milia Remover (salicylic acid 1% milia remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. Safety and efficacy in pediatric populations have not been established, and caution is warranted when considering its use in this demographic.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure safe use during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Dosage adjustments may be necessary for patients with reduced renal function. It is important to monitor renal function tests regularly in patients with known kidney problems. Additionally, a reduced dose should be considered in patients with a creatinine clearance of less than 30 mL/min.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted based on clinical judgment.

Overdosage

There is currently no specific information available regarding overdosage for this medication. In the absence of documented overdosage data, healthcare professionals are advised to exercise caution and monitor patients closely for any unusual symptoms or adverse effects that may arise following administration.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Continuous monitoring of vital signs and clinical status is essential. If symptoms of overdosage are observed, appropriate interventions should be implemented based on the patient's condition.

Healthcare professionals are encouraged to report any cases of suspected overdosage to the relevant authorities to contribute to the understanding of the medication's safety profile.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion or misuse. Patients should be informed that if they experience severe irritation while using the product, they should discontinue use immediately.

It is important for healthcare providers to instruct patients to monitor their condition closely. If the condition worsens or does not improve within four weeks, or if they experience severe redness, burning, or swelling, they should seek medical advice promptly.

Patients should also be cautioned to avoid contact with the eyes, lips, and mucous membranes. In the event of contact, they should rinse the area thoroughly with water. Additionally, healthcare providers should emphasize that the product should not be applied to broken, irritated, or sunburned skin, as this may lead to excessive drying or peeling.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. However, there are no specified storage or handling conditions provided in the current labeling information. Therefore, healthcare professionals are advised to refer to standard storage practices for similar products unless additional guidance is provided.

Additional Clinical Information

The product is administered topically, with a recommendation to apply a thin layer directly onto the milia (skin bumps) once or twice daily, as needed. Clinicians should advise patients who are pregnant or breastfeeding to consult a health professional prior to use. No additional information is available regarding laboratory tests, abuse potential, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Sylvirene Milia Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)